These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12564659)

  • 21. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.
    de Franciscis S; Gallelli L; Battaglia L; Molinari V; Montemurro R; Stillitano DM; Buffone G; Serra R
    Int Wound J; 2015 Jun; 12(3):250-3. PubMed ID: 23672237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
    J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cilostazol: treatment of intermittent claudication.
    Reilly MP; Mohler ER
    Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.
    Pande RL; Hiatt WR; Zhang P; Hittel N; Creager MA
    Vasc Med; 2010 Jun; 15(3):181-8. PubMed ID: 20385711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.
    Donnelly R
    Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S20-5. PubMed ID: 12180354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the cilostazol safety database.
    Pratt CM
    Am J Cardiol; 2001 Jun; 87(12A):28D-33D. PubMed ID: 11434897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
    Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cilostazol: improving walking distance in patients with intermittent claudication.
    Collinson DJ; Donnelly R
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
    Wang T; Elam MB; Forbes WP; Zhong J; Nakajima K
    Atherosclerosis; 2003 Dec; 171(2):337-42. PubMed ID: 14644405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of intermittent claudication: cilostazol.
    Collins P; Brittenden J
    Hosp Med; 2004 Aug; 65(8):466-70. PubMed ID: 15330347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF; Davie AM; Clegg JP
    Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
    Lee TM; Su SF; Hwang JJ; Tseng CD; Chen MF; Lee YT; Wang SS
    Atherosclerosis; 2001 Oct; 158(2):471-6. PubMed ID: 11583728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial.
    Hobbs SD; Marshall T; Fegan C; Adam DJ; Bradbury AW
    J Vasc Surg; 2007 Jan; 45(1):65-70; discussion 70. PubMed ID: 17210383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
    Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
    Hong H; Mackey WC
    Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.